Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Group sequential designs for negative binomial outcomes

Adaptive Designs for Sequential Experiments

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Adaptive two-stage seamless sequential design for clinical trials

Optimizing Interim Analysis Timing for Bayesian Adaptive Commensurate Designs

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart

Estimation of treatment effects following a sequential trial of multiple treatments

Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials

Optimization the Design of Fixed and Group Sequential Three-Arm Non-Inferiority Trials with Dichotomous Endpoints of Risk Difference and Odds Ratio

Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting

Sequential monitoring of response-adaptive randomized clinical trials